Si­lence Ther­a­peu­tics wants to list on Nas­daq while pur­su­ing new deals; Sur­face On­col­o­gy inks lat­est Keytru­da col­lab­o­ra­tion

→ Sur­face On­col­o­gy $SURF has joined the long line­up of biotechs to match one of their drugs with Mer­ck’s pow­er­house fran­chise ther­a­py Keytru­da. The biotech will col­lab­o­rate with Mer­ck on com­bin­ing Sur­face’s CD39-tar­get­ed SRF617 with the check­point in a Phase I/Ib in sol­id tu­mors.

→ Si­lence Ther­a­peu­tics — list­ed in Lon­don as $SLN — is jump­ing the At­lantic to Nas­daq. The biotech struck a deal with As­traZeneca re­cent­ly, and now wants to add to its list of col­lab­o­ra­tions. In a state­ment to­day, the com­pa­ny not­ed: “Fol­low­ing the re­cent an­nounce­ment of the mul­ti-tar­get As­traZeneca col­lab­o­ra­tion in March, the Com­pa­ny con­tin­ues to hold dis­cus­sions with a num­ber of third par­ties re­gard­ing pos­si­ble part­ner­ship and col­lab­o­ra­tion op­por­tu­ni­ties. Ac­cord­ing­ly, the Com­pa­ny is strength­en­ing its Busi­ness and Al­liance Man­age­ment ca­pa­bil­i­ty un­der the lead­er­ship of John Straf­ford, VP, Busi­ness De­vel­op­ment, with a view to ac­com­mo­dat­ing an ex­pan­sion of its ex­ist­ing third-par­ty re­la­tion­ships and, as ap­pro­pri­ate, ad­di­tion­al col­lab­o­ra­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER